Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT2216 and Irinotecan in Relapsed/Refractory Solid Tumors and Fibrolamellar Carcinoma
NCT06620302Phase 2Suspended
- Sponsor
- Children's Oncology Group
- Start
- Jun 2025
- Primary completion
- Dec 2031
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DT2216 in solid tumor and fibrolamellar carcinoma (FLC), sponsored by Children's Oncology Group. Primary endpoints: Incidence of adverse events, Dose-limiting toxicity up to 21 days and 8 more. Started Jun 2025; status: suspended.
02
Drugs
DT2216
03
Conditions
solid tumorfibrolamellar carcinoma (FLC)
Beyond the preview
Go deeper on NCT06620302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06620302.